Sophiris Bio Long Term Debt

Sophiris Bio (SPHS) currently reports a long-term debt of $3.1M as of September 2019. That compares with $5.8M in the prior-year period — down 46.3% year over year. Use the charts on this page to explore Sophiris Bio's long-term debt history and peer comparisons.

Sophiris Bio's long-term debt decreased from $5.8M to $3.1M — a 46.3% year-over-year decrease (period ending September 2019). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sophiris Bio reported $3.1M in long-term debt as of September 2019. That compares with $5.8M in the prior-year period — down 46.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $3.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sophiris Bio, and consider following SPHS for alerts when major investors trade the stock.

Sophiris Bio is classified in the Healthcare sector. On long-term debt, it currently shows $3.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPHS with unrelated industries.